ArticleScientific reports2025
Preliminary experimental study on a novel device using biomaterial for shunting fibrotic bleb following Ahmed glaucoma valve surgery in dogs.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Evidence architecture of glaucoma-related biomaterials reveals an uneven transition toward smart materials, additive manufacturing, and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to design and evaluate a novel trans-bleb device (TBD) for draining aqueous humor trapped within fibrotic blebs following Ahmed glaucoma valve (AGV) implantation in dogs. Two clinically normal, purpose-bred Beagles underwent AGV implantation surgery in one eye. When a bleb was formed with increased intraocular pressure (IOP), the TBD was inserted through a fenestration created in the bleb. IOP measurements, slit-lamp biomicroscopic and ultrasound biomicroscopic (UBM) evaluations were performed during follow-up. Results showed that IOP in the eyes undergoing AGV surgery was significantly lower than in the contralateral normal eye (P < .001). After 3 weeks, the IOP increased, and the UBM examination confirmed the presence of a bleb wall and an underlying cavity. After TBD application surgery, a significant decrease in IOP was observed (P < .001). Histological findings indicated that the TBD effectively penetrated the fibrotic membrane surrounding the AGV, with observed mild inflammatory cell infiltration, neovascularization, and myofibroblast differentiation, suggesting filtering bleb formation. The TBD may offer a novel approach to address bleb fibrosis-related failure following glaucoma surgery, restoring aqueous humor flow, and thus reducing IOP. Further research is needed to validate its effectiveness, optimize its design, and assess long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.